Vaccine To Centre For Rs 250, Rs 1,000 To Pharmacies

Andrew Cummings
November 23, 2020

The Oxford COVID-19 vaccine will be priced at a maximum of Rs 1,000 for two necessary doses for the public, (depending on the final trial results and regulatory approvals), said Serum Institute of India's CEO Adar Poonawalla.

Earlier on Monday, the Oxford-AstraZeneca team announced that one of the dosing regimens of the vaccine might be 90% effective in preventing COVID-19 infection. "So I've kept it in that priority", said Mr. Poonawalla, referencing the global COVAX facility, which has been set up to provide COVID-19 vaccines to poorer countries. He also asserted that the vaccine will be available for healthcare workers and elderly people by around February 2021 and for the general public by April, news agencies IANS and PTI reported.

He said that the government will get the vaccine at a much lower price of around $3-$4 (approximately Rs 225-300) as they will be buying large volumes.


Asked at what price the public will get it, he said it will be around Dollars 5-6 per dose with an MRP of around Rs 1,000 for the two necessary doses. "So, you have the vaccine for - again - the vulnerable populations by Jan-Feb and then March-April for the general public", he further added.

Poonawalla said the vaccine would cost Rs 500 to Rs 600 for the public.

SII is now conducting clinical trials of Oxford University-AstraZeneca's COVID-19 vaccine candidate in India.


Serum Institute of India is seeking the drug regulator's nod for limited use of the vaccine on frontline workers and elderly.

AstraZeneca said on Monday that an interim analysis of clinical trials of its COVID-19 vaccine in the United Kingdom and Brazil showed that it was 70 per cent effective on average, becoming the third drugmaker to announce promising results to contain the deadly virus.

"If all that goes according to plan, these are the timelines we are looking at".


Poonawalla said 30-40 crore doses of the Oxford vaccine will be available by the first quarter of 2021. Currently, the company is working at 50 to 60 million dose capacity per month output. These additional facilities are now getting validated.

Other reports by iNewsToday

FOLLOW OUR NEWSPAPER